Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity
The progress of medical technology and scientific advances in the field of anticancer treatment have increased the survival probabilities and duration of life of patients. However, cancer-therapy-induced cardiac dysfunction remains a clinically salient problem. Effective anticancer therapies may eve...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/11/2764 |
| _version_ | 1797469031837466624 |
|---|---|
| author | Ping-Hsien Wang Yi-Hsien Fang Yen-Wen Liu Min-Long Yeh |
| author_facet | Ping-Hsien Wang Yi-Hsien Fang Yen-Wen Liu Min-Long Yeh |
| author_sort | Ping-Hsien Wang |
| collection | DOAJ |
| description | The progress of medical technology and scientific advances in the field of anticancer treatment have increased the survival probabilities and duration of life of patients. However, cancer-therapy-induced cardiac dysfunction remains a clinically salient problem. Effective anticancer therapies may eventually induce cardiomyopathy. To date, several studies have focused on the mechanisms underlying cancer-treatment-related cardiotoxicity. Cardiomyocyte cell lines with no contractile physiological characteristics cannot adequately model “true” human cardiomyocytes. However, applying “true” human cardiomyocytes for research is fraught with many obstacles (e.g., invasiveness of the procedure), and there is a proliferative limitation for rodent primary cultures. Human-induced pluripotent stem-cell-differentiated cardiomyocytes (hiPSC-CMs), which can be produced efficiently, are viable candidates for mimicking human cardiomyocytes in vitro. We successfully performed cardiac differentiation of human iPSCs to obtain hiPSC-CMs. These hiPSC-CMs can be used to investigate the pathophysiological basis and molecular mechanism of cancer-treatment-related cardiotoxicity and to develop novel strategies to prevent and rescue such cardiotoxicity. We propose that hiPSC-CMs can be used as an in vitro drug screening platform to study targeted cancer-therapy-related cardiotoxicity. |
| first_indexed | 2024-03-09T19:15:41Z |
| format | Article |
| id | doaj.art-edaf8362a4f6499e97fb0047b7f65f85 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T19:15:41Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-edaf8362a4f6499e97fb0047b7f65f852023-11-24T03:50:19ZengMDPI AGBiomedicines2227-90592022-10-011011276410.3390/biomedicines10112764Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug ToxicityPing-Hsien Wang0Yi-Hsien Fang1Yen-Wen Liu2Min-Long Yeh3Department of Biomedical Engineering, National Cheng Kung University, Tainan 70140, TaiwanCenter of Cell therapy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, TaiwanDivision of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, TaiwanDepartment of Biomedical Engineering, National Cheng Kung University, Tainan 70140, TaiwanThe progress of medical technology and scientific advances in the field of anticancer treatment have increased the survival probabilities and duration of life of patients. However, cancer-therapy-induced cardiac dysfunction remains a clinically salient problem. Effective anticancer therapies may eventually induce cardiomyopathy. To date, several studies have focused on the mechanisms underlying cancer-treatment-related cardiotoxicity. Cardiomyocyte cell lines with no contractile physiological characteristics cannot adequately model “true” human cardiomyocytes. However, applying “true” human cardiomyocytes for research is fraught with many obstacles (e.g., invasiveness of the procedure), and there is a proliferative limitation for rodent primary cultures. Human-induced pluripotent stem-cell-differentiated cardiomyocytes (hiPSC-CMs), which can be produced efficiently, are viable candidates for mimicking human cardiomyocytes in vitro. We successfully performed cardiac differentiation of human iPSCs to obtain hiPSC-CMs. These hiPSC-CMs can be used to investigate the pathophysiological basis and molecular mechanism of cancer-treatment-related cardiotoxicity and to develop novel strategies to prevent and rescue such cardiotoxicity. We propose that hiPSC-CMs can be used as an in vitro drug screening platform to study targeted cancer-therapy-related cardiotoxicity.https://www.mdpi.com/2227-9059/10/11/2764cardiotoxicityhuman-induced pluripotent stem cell (hiPSC)cardiomyocyte (CM)cardiac differentiationH9c2hepatocellular carcinoma (HCC) |
| spellingShingle | Ping-Hsien Wang Yi-Hsien Fang Yen-Wen Liu Min-Long Yeh Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity Biomedicines cardiotoxicity human-induced pluripotent stem cell (hiPSC) cardiomyocyte (CM) cardiac differentiation H9c2 hepatocellular carcinoma (HCC) |
| title | Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity |
| title_full | Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity |
| title_fullStr | Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity |
| title_full_unstemmed | Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity |
| title_short | Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity |
| title_sort | merits of hipsc derived cardiomyocytes for in vitro research and testing drug toxicity |
| topic | cardiotoxicity human-induced pluripotent stem cell (hiPSC) cardiomyocyte (CM) cardiac differentiation H9c2 hepatocellular carcinoma (HCC) |
| url | https://www.mdpi.com/2227-9059/10/11/2764 |
| work_keys_str_mv | AT pinghsienwang meritsofhipscderivedcardiomyocytesforinvitroresearchandtestingdrugtoxicity AT yihsienfang meritsofhipscderivedcardiomyocytesforinvitroresearchandtestingdrugtoxicity AT yenwenliu meritsofhipscderivedcardiomyocytesforinvitroresearchandtestingdrugtoxicity AT minlongyeh meritsofhipscderivedcardiomyocytesforinvitroresearchandtestingdrugtoxicity |